Press Releases Items Per Page 102550 Year None202220212020201920182017201620152014 05-16-2022 Daré Bioscience to Participate in H.C. Wainwright Global Investment Conference 05-12-2022 Daré Bioscience Reports First Quarter 2022 Financial Results and Provides a Company Update 05-11-2022 Daré Bioscience Announces NIH Grant Award 05-05-2022 Daré Bioscience to Host First Quarter 2022 Financial Results and Company Update Conference Call and Webcast on May 12, 2022 04-14-2022 Daré Bioscience to Participate in Upcoming Conference 04-12-2022 Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-HRT1 03-31-2022 Daré Bioscience Reports Full-Year 2021 Financial Results and Provides a Company Update 03-31-2022 Organon Enters into Global License Agreement to Commercialize Daré Bioscience’s XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis (BV) 03-24-2022 Daré Bioscience to Host Full-year 2021 Financial Results and Company Update Conference Call and Webcast on March 31, 2022 03-22-2022 Daré Bioscience to Present at the Maxim 2022 Virtual Growth Conference Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 13
05-12-2022 Daré Bioscience Reports First Quarter 2022 Financial Results and Provides a Company Update
05-05-2022 Daré Bioscience to Host First Quarter 2022 Financial Results and Company Update Conference Call and Webcast on May 12, 2022
03-31-2022 Organon Enters into Global License Agreement to Commercialize Daré Bioscience’s XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis (BV)
03-24-2022 Daré Bioscience to Host Full-year 2021 Financial Results and Company Update Conference Call and Webcast on March 31, 2022
